CD28-Directed T Cell Costimulation Blockade with Abatacept to Prevent GVHD During High-Risk Unrelated HSCT: A First-In-Disease Trial
Year: 2012
Type: article
Study design: Clinical Trial
Abstract: We describe a first-in-disease trial of CD28-directed costimulation blockade to prevent GvHD after URD HSCT in patients >12y with advanced heme malignancies (Clinical Trials.Org #NCT01012492). In this trial, 10 mg/kg abatacept is administered on d -1, +5, +14, and +28 in addition to standard GvHD prophylaxis (cyclosporine + methotrexate). 10 of 11 planned patients have enrolled, of which 8 are evaluable for engraftment and toxicity, and 5 are evaluable for the primary immunologic outcome of the study: the incidence of steroid-requiring GvHD at d+100 post-transplant.
Authors: L.S. Kean, A. Langston, M. Qayed, J. Khoury, D. Tiwari, C. Couture, H. Renfroe, S. Sen, J. Robertson, E.K. Waller, J. Horan
Institution: Emory University
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $3,650
OpenAlex ID: W2167944794